In September 2016, we entered into a strategic licensing collaboration with Janssen Pharmaceutica N.V., for an asset from Janssen’s early oncology development portfolio. The agreement grants us the rights to develop TRC253 (formerly JNJ-63576253), a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors which display drug resistance to currently approved treatments, which is intended for the treatment of men with prostate cancer.
In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications, including wet AMD. In June 2015, Santen filed an IND with the FDA, for the initiation of clinical studies for DE-122 in patients with wet AMD. DE-122 is the ophthalmic formulation of our proprietary endoglin antibody, TRC105. Santen is currently enrolling patients with wet AMD in a Phase 2 study comparing the combination of DE-122 with Lucentis® versus Lucentis alone.
In November 2018 we entered into a series of strategic collaborative partnerships for developing multiple immuno-oncology programs with I-Mab Biopharma, a China-based clinical stage biopharmaceutical company, including I-Mab’s proprietary CD73 antibody TJD5, a novel immuno-oncology asset with best-in-class potential from I-Mab’s broad immuno-oncology portfolio, as well asseveral proprietary bispecific antibodies under development by I-Mab.